Prestige Consumer Healthcare (NYSE:PBH) Hits New 1-Year Low – Should You Sell?

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) hit a new 52-week low on Friday . The stock traded as low as $58.50 and last traded at $59.2730, with a volume of 45799 shares trading hands. The stock had previously closed at $59.99.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PBH shares. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a report on Wednesday, October 8th. Oppenheimer cut their target price on Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Canaccord Genuity Group reduced their price objective on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Sidoti raised Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price objective for the company in a report on Wednesday, September 24th. Finally, Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $85.33.

Prestige Consumer Healthcare Stock Down 1.0%

The company has a quick ratio of 2.99, a current ratio of 4.38 and a debt-to-equity ratio of 0.55. The company has a 50-day simple moving average of $62.44 and a two-hundred day simple moving average of $72.69. The stock has a market cap of $2.85 billion, a P/E ratio of 13.94, a P/E/G ratio of 1.93 and a beta of 0.41.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $1.07 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The company had revenue of $274.11 million during the quarter, compared to analyst estimates of $257.14 million. Prestige Consumer Healthcare had a net margin of 19.02% and a return on equity of 12.69%. The firm’s revenue was down 3.4% compared to the same quarter last year. During the same period in the prior year, the business posted $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its holdings in shares of Prestige Consumer Healthcare by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company’s stock valued at $161,723,000 after acquiring an additional 119,459 shares in the last quarter. Allspring Global Investments Holdings LLC increased its position in Prestige Consumer Healthcare by 4.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company’s stock valued at $100,893,000 after purchasing an additional 70,376 shares during the period. Kayne Anderson Rudnick Investment Management LLC raised its holdings in Prestige Consumer Healthcare by 45.3% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,580,819 shares of the company’s stock worth $135,903,000 after purchasing an additional 493,199 shares in the last quarter. Geode Capital Management LLC raised its holdings in Prestige Consumer Healthcare by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,413,041 shares of the company’s stock worth $112,843,000 after purchasing an additional 9,455 shares in the last quarter. Finally, Invesco Ltd. lifted its position in shares of Prestige Consumer Healthcare by 24.7% in the 1st quarter. Invesco Ltd. now owns 1,321,800 shares of the company’s stock worth $113,635,000 after purchasing an additional 261,537 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.